Hikma Pharmaceuticals Plc on Friday backed its forecast for the full-year, boosted by higher demand for its injectable drugs and a rebound in its generics business."Across our three businesses, we are driving good demand for our broad product portfolio and recent product launches," Chief Executive Officer Siggi Olafsson said.
Hikma expects annual revenue from its injectables division to be between $850 million and $900 million and its generics unit to be between $650 million and $700 million.